COVID-19: Sapropterin dihydrochloride
Sapropterin dihydrochloride has been funded since November 2018 for patients that are pregnant or actively planning to become pregnant with phenylketonuria (PKU) in subject to Special Authority criteria.
Page updated: 9 April 2020
Renewal of Special Authority
We have removed the requirement for a metabolic physician to apply for renewals of the Special Authority to fund sapropterin dihydrochloride.
Any relevant physician can apply to renew the Special Authority.
Section H of the Pharmaceutical Schedule will also be amended to reflect this change.
Changes are temporary
We intend change the criteria back to the current status once health services have stabilised to a point where it becomes practical to reinstate them.
Who to contact
If you have any questions about this change, email email@example.com
Last updated: 15 April 2020